- Acorda Therapeutics Inc ACOR has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.
- Inbrija is indicated in the E.U. for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
- Under the terms of the supply agreement, Acorda will receive a double-digit percentage of the selling price of Inbrija.
- Esteve has exclusive distribution rights to Inbrija in the territory, and it will launch the product in Spain in Q4 of 2022.
- Price Action: ACOR shares are up 49.3% at $5.69 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
